Evidence for sexual dimorphism of estrogen receptors in hypothalamus and thymus of neonatal and immature Wistar rats.
It is hypothesized that the rat thymus is sexually differentiated. To begin testing this, we used the 5-day-old rat, whose hypothalamus is sexually differentiated during this period. Cytosolic estrogen receptors (ER) were measured in cytosols prepared from the brain, thymus and uterus of Wistar rats at 5, 18 and 30 days post-partum. ER concentrations were significantly higher in hypothalamus in cytosols of female 5-day-old rats, and this difference had disappeared by day 18. The pattern in thymus was identical to that observed in hypothalamus, suggesting the presence in the thymus of the aromatase system that converts androgen to estrogen, and that estrogen-mediated sexual differentiation of thymus might be proceeding at 5 days. Unlike the case for hypothalamus, no experimental model exists at present for testing functional sexual differentiation in thymus. Therefore we tested the effects of aromatase inhibitors on estrogen receptor activity in thymus well after the five-day period, and before atrophy of the thymus has commenced. Male and female rats were implanted at 15 days of age with SILASTIC implants containing 5 mg of estradiol or with 25 mg of the aromatase inhibitor 4-hydroxyandrostenedione (4-OHA) and cytosolic ER prepared at 30 days and activity measured. Administration of estradiol resulted in failure to detect available receptor, suggesting that the binding components measured were ER. After 4-OHA administration, ER concentrations were significantly increased in cytosols from male but not female hypothalamus and thymus. There is therefore a basis for exploring further the hypothesis that rat thymus is sexually differentiated.
de Fougerolles Nunn
E
E
Schiller International University, London, UK.
Greenstein
B
B
Khamashta
M
M
Hughes
G R
GR
D000367:Age Factors; D000735:Androstenedione / Q000031:analogs & derivatives / Q000494:pharmacology; D000818:Animals; D047072:Aromatase Inhibitors; D003600:Cytosol / Q000737:chemistry; D004343:Drug Implants; D004958:Estradiol / Q000008:administration & dosage / Q000494:pharmacology; D005260:Female; D007031:Hypothalamus / Q000737:chemistry* / Q000187:drug effects / Q000254:growth & development; D008297:Male; D051381:Rats; D017208:Rats, Wistar; D011960:Receptors, Estrogen / Q000032:analysis* / Q000187:drug effects; D012727:Sex Characteristics; D012733:Sex Differentiation; D012741:Sexual Maturation; D013950:Thymus Gland / Q000737:chemistry* / Q000187:drug effects / Q000254:growth & development; D014599:Uterus / Q000737:chemistry / Q000187:drug effects
D047072:Aromatase Inhibitors; D004343:Drug Implants; D011960:Receptors, Estrogen; D000735:Androstenedione; D004958:Estradiol; C014594:formestane